- Home
- TPST vs CLPS Comparison
TPST vs CLPS Comparison
Compare TPST & CLPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- CLPS
- Stock Information
- Founded
- TPST 2011
- CLPS 2005
- Country
- TPST United States
- CLPS Hong Kong
- Employees
- TPST N/A
- CLPS N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- CLPS Computer Software: Prepackaged Software
- Sector
- TPST Health Care
- CLPS Technology
- Exchange
- TPST Nasdaq
- CLPS Nasdaq
- Market Cap
- TPST 33.0M
- CLPS 26.9M
- IPO Year
- TPST N/A
- CLPS 2018
- Fundamental
- Price
- TPST $7.54
- CLPS $0.91
- Analyst Decision
- TPST Hold
- CLPS
- Analyst Count
- TPST 3
- CLPS 0
- Target Price
- TPST $30.00
- CLPS N/A
- AVG Volume (30 Days)
- TPST 94.0K
- CLPS 11.6K
- Earning Date
- TPST 08-11-2025
- CLPS 03-05-2025
- Dividend Yield
- TPST N/A
- CLPS 14.44%
- EPS Growth
- TPST N/A
- CLPS N/A
- EPS
- TPST N/A
- CLPS N/A
- Revenue
- TPST N/A
- CLPS $153,816,045.00
- Revenue This Year
- TPST N/A
- CLPS N/A
- Revenue Next Year
- TPST N/A
- CLPS N/A
- P/E Ratio
- TPST N/A
- CLPS N/A
- Revenue Growth
- TPST N/A
- CLPS 5.81
- 52 Week Low
- TPST $5.35
- CLPS $0.68
- 52 Week High
- TPST $28.34
- CLPS $1.70
- Technical
- Relative Strength Index (RSI)
- TPST 56.78
- CLPS 39.86
- Support Level
- TPST $7.13
- CLPS $0.90
- Resistance Level
- TPST $8.75
- CLPS $0.97
- Average True Range (ATR)
- TPST 0.47
- CLPS 0.05
- MACD
- TPST 0.12
- CLPS -0.01
- Stochastic Oscillator
- TPST 54.17
- CLPS 3.85
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About CLPS CLPS Incorporation
CLPS Inc is a holding company. The company through its subsidiaries provides information technology consulting and solutions institutions in the banking, insurance, and financial sectors, both in China and globally. Its products are Risk Control Platform, Transaction Acquiring Platform, Debt Collection Platform, Virtual Bank Training Platform, Credit Card System, and other related products. The company generates its revenue from IT consulting services, Customized IT solution services, and others. Generating the majority of its revenue from the IT consulting service.